Marino Stram & Associates LLC Raises Stock Position in Kenvue Inc. (NYSE:KVUE)

Marino Stram & Associates LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 20.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,449 shares of the company’s stock after purchasing an additional 2,487 shares during the quarter. Marino Stram & Associates LLC’s holdings in Kenvue were worth $311,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Empirical Finance LLC bought a new stake in Kenvue during the third quarter valued at approximately $336,000. UniSuper Management Pty Ltd bought a new stake in Kenvue during the third quarter valued at approximately $35,544,000. Howland Capital Management LLC bought a new stake in Kenvue during the third quarter valued at approximately $7,764,000. Citizens Business Bank bought a new stake in Kenvue during the third quarter valued at approximately $2,507,000. Finally, Fifth Third Bancorp lifted its holdings in shares of Kenvue by 35.3% in the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after acquiring an additional 72,435 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on KVUE. The Goldman Sachs Group began coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. lowered their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Finally, UBS Group upped their price target on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Trading Down 1.2 %

Shares of NYSE:KVUE traded down $0.23 during midday trading on Tuesday, reaching $18.90. The company’s stock had a trading volume of 10,519,206 shares, compared to its average volume of 16,728,441. The firm has a 50 day moving average of $19.88 and a 200-day moving average of $20.18. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s quarterly revenue was down 2.7% compared to the same quarter last year. As a group, analysts predict that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.23%. The ex-dividend date of this dividend was Tuesday, February 13th.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.